NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; NTBI 1301; NY ESO-1 loaded dendritic cell vaccine
- Indications Solid tumours
- Focus Adverse reactions
- 26 Feb 2019 Status changed from recruiting to discontinued.
- 20 Dec 2018 Results safety, feasibility, and antitumor efficacy of transgenic ACT with DC vaccination, with and without CTLA-4 blockade with ipilimumab from NCT02070406 and NCT01697527, published in the Clinical Cancer Research.
- 12 Sep 2017 Planned End Date changed from 1 Feb 2019 to 17 Jul 2020.